Inventiva Announces Results Of QT/QTc Study Conducted With Lanifibranor’ Says ‘Lanifibranor administered at the anticipated maximal therapeutic dose of 1200mg/day and at the supra-therapeutic dose of 2400mg/day had no impact on QT/QTc interval’